Karuna Therapeutics to Present at Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Karuna Therapeutics Inc. (KRTX) PT Raised to $175 at Oppenheimer
November 8, 2021 6:33 AM ESTOppenheimer analyst Jay Olson raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $175.00 (from $148.00) while maintaining an Outperform rating.
The analyst commented, "KRTX reported 3Q21 results with OpEx of $51M and cash of ~$500M. We highlight key progress and catalysts,... More
